<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02061384</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00000564</org_study_id>
    <nct_id>NCT02061384</nct_id>
  </id_info>
  <brief_title>RA-2 13-cis Retinoic Acid (Isotretinoin)</brief_title>
  <acronym>RA-2</acronym>
  <official_title>A Pilot Trial of 13-cis Retinoic Acid (Isotretinoin) for the Treatment of Men With Oligoasthenoteratozoospermia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Men with infertility and normal hormone levels have few options for fertility treatment.&#xD;
      Previous research work has suggested that men with infertility may have low levels of the&#xD;
      active form of Vitamin A, called retinoic acid, in their testes. We think that giving men&#xD;
      with low sperm counts retinoic acid may increase their sperm counts and improve their chances&#xD;
      of fathering a pregnancy. We want to see if retinoic acid administration over twenty weeks&#xD;
      can increase sperm production and help infertile men become fathers without the need for In&#xD;
      vitro fertilization (IVF) and/or intracytoplasmic sperm injection (ICSI). We also want to see&#xD;
      if adding calcitriol with retinoic acid will improve sperm motility in a sub-set of subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 20 week, unblinded, two-arm pilot study to determine the impact of therapy with&#xD;
      13-cis retinoic acid and calcitriol on sperm indices in infertile men. Twenty infertile men,&#xD;
      ages 21-60 with abnormal sperm analyses will be enrolled for 20-week and given 20 mg 13-cis&#xD;
      retinoic acid, twice daily. Subjects#11-#20 will also be administered calcitriol to see if&#xD;
      adding calcitriol with Accutane will improve sperm motility. All subjects will be closely&#xD;
      followed for side effects related to treatment. The impact of treatment on indices of&#xD;
      spermatogenesis will be determined by monthly seminal fluid analyses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Millions of Sperm Per Ejaculate</measure>
    <time_frame>Up to 20-weeks</time_frame>
    <description>Millions of sperm per ejaculate in men treated with 13-cis retinoic acid</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Male Infertility</condition>
  <condition>Klinefelter's Syndrome</condition>
  <condition>Y-chromosome Microdeletions</condition>
  <arm_group>
    <arm_group_label>13-cis retinoic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20mg 13-cis retinoic acid twice daily (BID) with meals for 20 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcitriol 0.25 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral calcitriol 025 mcg BID subjects 11-20 for 20 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>13-cis retinoic acid</intervention_name>
    <description>Accutane is used for the treatment of severe acne</description>
    <arm_group_label>13-cis retinoic acid</arm_group_label>
    <arm_group_label>Calcitriol 0.25 mcg</arm_group_label>
    <other_name>Accutane</other_name>
    <other_name>Isotretinoin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcitriol</intervention_name>
    <description>Calcitriol is a form of vitamin D given twice daily (BID)</description>
    <arm_group_label>Calcitriol 0.25 mcg</arm_group_label>
    <other_name>1,25-dihydroxyvitamin D3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects will be infertile men (no pregnancy with partner with normal cycles and&#xD;
             normal hysterosalpingogram despite &gt;1 year of unprotected intercourse).&#xD;
&#xD;
          -  Abnormal sperm analyses with a total, motile sperm count of less than 10 million sperm&#xD;
             as assessed by semen analysis on two occasions separated by one week.&#xD;
&#xD;
          -  In the opinion of the investigator, is able to comply with the protocol, understand&#xD;
             and sign an informed consent and HIPAA (Health Insurance Portability and&#xD;
             Accountability Act ) form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Men participating in another clinical trial&#xD;
&#xD;
          -  Men not living in the catchment area of the clinic&#xD;
&#xD;
          -  Clinically significant abnormal findings at screening&#xD;
&#xD;
          -  Known genetic infertility (e.g. Klinefelter syndrome or Y-chromosome microdeletions),&#xD;
&#xD;
          -  Hypogonadotropic hypogonadism (that might respond to gonadotropin injections),&#xD;
&#xD;
          -  The use of anabolic steroids, illicit drugs, or the consumption of more than 4&#xD;
             alcoholic beverages daily&#xD;
&#xD;
          -  Severe mental health problems requiring medications&#xD;
&#xD;
          -  Current therapy with retinoic acid (e.g. Accutane) or vitamin A.&#xD;
&#xD;
          -  Score of greater than 15 on the Patient health questionnaire (PHQ9).&#xD;
&#xD;
          -  Abnormal serum chemistry values according to local laboratory normal values which&#xD;
             indicate liver or kidney dysfunction. Other abnormal lab values may also be&#xD;
             exclusionary, at the discretion of the investigator&#xD;
&#xD;
          -  Men with a personal history of serious psychiatric disorders&#xD;
&#xD;
          -  Men currently receiving tetracycline containing medications&#xD;
&#xD;
          -  Men currently receiving phenytoin&#xD;
&#xD;
          -  Men with a history of inflammatory bowel disease&#xD;
&#xD;
          -  Men with a history of bone disease&#xD;
&#xD;
          -  Men who have used isotretinoin within eight weeks of the start of dosing&#xD;
&#xD;
          -  Men with elevated serum triglycerides&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John K Amory, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jequier AM, Holmes SC. Primary testicular disease presenting as azoospermia or oligozoospermia in an infertility clinic. Br J Urol. 1993 Jun;71(6):731-5.</citation>
    <PMID>8102079</PMID>
  </reference>
  <reference>
    <citation>de Kretser DM. Male infertility. Lancet. 1997 Mar 15;349(9054):787-90. Review.</citation>
    <PMID>9074589</PMID>
  </reference>
  <reference>
    <citation>Schlegel PN. Nonobstructive azoospermia: a revolutionary surgical approach and results. Semin Reprod Med. 2009 Mar;27(2):165-70. doi: 10.1055/s-0029-1202305. Epub 2009 Feb 26. Review.</citation>
    <PMID>19247918</PMID>
  </reference>
  <reference>
    <citation>Napoli JL. Retinoic acid: its biosynthesis and metabolism. Prog Nucleic Acid Res Mol Biol. 1999;63:139-88. Review.</citation>
    <PMID>10506831</PMID>
  </reference>
  <reference>
    <citation>Center for Disease Control. Infertility Facts,m accessed at http://www.ede.gov/nchs/fastats/fertile.htm (June 3, 2013)</citation>
  </reference>
  <reference>
    <citation>Doyle TJ, Braun KW, McLean DJ, Wright RW, Griswold MD, Kim KH. Potential functions of retinoic acid receptor A in Sertoli cells and germ cells during spermatogenesis. Ann N Y Acad Sci. 2007 Dec;1120:114-30. Epub 2007 Sep 28.</citation>
    <PMID>17905941</PMID>
  </reference>
  <reference>
    <citation>Koubova J, Menke DB, Zhou Q, Capel B, Griswold MD, Page DC. Retinoic acid regulates sex-specific timing of meiotic initiation in mice. Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2474-9. Epub 2006 Feb 6.</citation>
    <PMID>16461896</PMID>
  </reference>
  <reference>
    <citation>Anderson EL, Baltus AE, Roepers-Gajadien HL, Hassold TJ, de Rooij DG, van Pelt AM, Page DC. Stra8 and its inducer, retinoic acid, regulate meiotic initiation in both spermatogenesis and oogenesis in mice. Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14976-80. doi: 10.1073/pnas.0807297105. Epub 2008 Sep 17.</citation>
    <PMID>18799751</PMID>
  </reference>
  <reference>
    <citation>Chung SS, Wang X, Wolgemuth DJ. Expression of retinoic acid receptor alpha in the germline is essential for proper cellular association and spermiogenesis during spermatogenesis. Development. 2009 Jun;136(12):2091-100. doi: 10.1242/dev.020040.</citation>
    <PMID>19465599</PMID>
  </reference>
  <reference>
    <citation>Dufour JM, Kim KH. Cellular and subcellular localization of six retinoid receptors in rat testis during postnatal development: identification of potential heterodimeric receptors. Biol Reprod. 1999 Nov;61(5):1300-8.</citation>
    <PMID>10529278</PMID>
  </reference>
  <reference>
    <citation>Lohnes D, Kastner P, Dierich A, Mark M, LeMeur M, Chambon P. Function of retinoic acid receptor gamma in the mouse. Cell. 1993 May 21;73(4):643-58.</citation>
    <PMID>8388780</PMID>
  </reference>
  <reference>
    <citation>Lufkin T, Lohnes D, Mark M, Dierich A, Gorry P, Gaub MP, LeMeur M, Chambon P. High postnatal lethality and testis degeneration in retinoic acid receptor alpha mutant mice. Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7225-9.</citation>
    <PMID>8394014</PMID>
  </reference>
  <reference>
    <citation>Kastner P, Mark M, Leid M, Gansmuller A, Chin W, Grondona JM, Décimo D, Krezel W, Dierich A, Chambon P. Abnormal spermatogenesis in RXR beta mutant mice. Genes Dev. 1996 Jan 1;10(1):80-92.</citation>
    <PMID>8557197</PMID>
  </reference>
  <reference>
    <citation>Ghyselinck NB, Vernet N, Dennefeld C, Giese N, Nau H, Chambon P, Viville S, Mark M. Retinoids and spermatogenesis: lessons from mutant mice lacking the plasma retinol binding protein. Dev Dyn. 2006 Jun;235(6):1608-22.</citation>
    <PMID>16586441</PMID>
  </reference>
  <reference>
    <citation>Hoting VE, Schütte B, Schirren C. [Isotretinoin treatment of acne conglobata. Andrologic follow-up]. Fortschr Med. 1992 Aug 20;110(23):427-30. German.</citation>
    <PMID>1398387</PMID>
  </reference>
  <reference>
    <citation>Vogt HJ, Ewers R. [13-cis-Retinoic acid and spermatogenesis. Spermatological and impulse cytophotometric studies]. Hautarzt. 1985 May;36(5):281-6. German.</citation>
    <PMID>3159708</PMID>
  </reference>
  <reference>
    <citation>Török L, Kádár L, Kása M. Spermatological investigations in patients treated with etretinate and isotretinoin. Andrologia. 1987 Nov-Dec;19(6):629-33.</citation>
    <PMID>3481225</PMID>
  </reference>
  <reference>
    <citation>Nya-Ngatchou JJ, Arnold SL, Walsh TJ, Muller CH, Page ST, Isoherranen N, Amory JK. Intratesticular 13-cis retinoic acid is lower in men with abnormal semen analyses: a pilot study. Andrology. 2013 Mar;1(2):325-31. doi: 10.1111/j.2047-2927.2012.00033.x. Epub 2012 Nov 29.</citation>
    <PMID>23413144</PMID>
  </reference>
  <reference>
    <citation>World Health Organization. [Laboratory manual of the WHO for the examination of human semen and sperm-cervical mucus interaction]. Ann Ist Super Sanita. 2001;37(1):I-XII, 1-123. Italian.</citation>
    <PMID>11680039</PMID>
  </reference>
  <reference>
    <citation>Christiansen C, Christensen MS, Rødbro P, Hagen C, Transbøl I. Effect of 1,25-dihydroxy-vitamin D3 in itself or combined with hormone treatment in preventing postmenopausal osteoporosis. Eur J Clin Invest. 1981 Aug;11(4):305-9.</citation>
    <PMID>6795047</PMID>
  </reference>
  <reference>
    <citation>Riggs BL, Nelson KI. Effect of long term treatment with calcitriol on calcium absorption and mineral metabolism in postmenopausal osteoporosis. J Clin Endocrinol Metab. 1985 Sep;61(3):457-61.</citation>
    <PMID>3926808</PMID>
  </reference>
  <reference>
    <citation>Falch JA, Odegaard OR, Finnanger AM, Matheson I. Postmenopausal osteoporosis: no effect of three years treatment with 1,25-dihydroxycholecalciferol. Acta Med Scand. 1987;221(2):199-204.</citation>
    <PMID>3035879</PMID>
  </reference>
  <reference>
    <citation>Caniggia A, Nuti R, Lore F, Martini G, Turchetti V, Righi G. Long-term treatment with calcitriol in postmenopausal osteoporosis. Metabolism. 1990 Apr;39(4 Suppl 1):43-9.</citation>
    <PMID>2325571</PMID>
  </reference>
  <reference>
    <citation>Ott SM, Chesnut CH 3rd. Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Intern Med. 1989 Feb 15;110(4):267-74.</citation>
    <PMID>2913914</PMID>
  </reference>
  <reference>
    <citation>Gallagher JC, Fowler SE, Detter JR, Sherman SS. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. J Clin Endocrinol Metab. 2001 Aug;86(8):3618-28.</citation>
    <PMID>11502787</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 10, 2014</study_first_submitted>
  <study_first_submitted_qc>February 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2014</study_first_posted>
  <results_first_submitted>April 26, 2021</results_first_submitted>
  <results_first_submitted_qc>July 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 30, 2021</results_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>John Amory</investigator_full_name>
    <investigator_title>Professor, General Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Infertility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Male</mesh_term>
    <mesh_term>Klinefelter Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitriol</mesh_term>
    <mesh_term>Dihydroxycholecalciferols</mesh_term>
    <mesh_term>Tretinoin</mesh_term>
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 29, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT02061384/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 22, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT02061384/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>13-cis Retinoic Acid + Oral Calcitriol</title>
          <description>20 mg 13-cis retinoic acid twice daily (BID) with meals for two weeks + oral calcitriol 0.25 mcg BID</description>
        </group>
        <group group_id="P2">
          <title>13-cis Retinoic Acid</title>
          <description>20 mg 13-cis retinoic acid twice daily (BID) with meals for 20 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Sixteen men completed all study procedures, and three men discontinued treatment early.</population>
      <group_list>
        <group group_id="B1">
          <title>13-cis Retinoic Acid</title>
          <description>20mg 13-cis retinoic acid twice daily (BID) with meals for 20 weeks&#xD;
13-cis retinoic acid: Accutane is used for the treatment of severe acne</description>
        </group>
        <group group_id="B2">
          <title>13-cis Retinoic Acid + Calcitriol 0.25 mcg</title>
          <description>oral calcitriol 025 mcg BID subjects 11-20 for 20 weeks&#xD;
Calcitriol: Calcitriol is a form of vitamin D given twice daily (BID)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.1" spread="5.32"/>
                    <measurement group_id="B2" value="34" spread="3.4"/>
                    <measurement group_id="B3" value="34.61" spread="4.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Millions of Sperm Per Ejaculate</title>
        <description>Millions of sperm per ejaculate in men treated with 13-cis retinoic acid</description>
        <time_frame>Up to 20-weeks</time_frame>
        <population>First 10 men received isotretinoin alone, next 10 men received both isotretinoin and calcitriol</population>
        <group_list>
          <group group_id="O1">
            <title>13-cis Retinoic Acid</title>
            <description>20mg 13-cis retinoic acid twice daily (BID) with meals for 20 weeks&#xD;
13-cis retinoic acid: Accutane is used for the treatment of severe acne</description>
          </group>
          <group group_id="O2">
            <title>Calcitriol 0.25 mcg</title>
            <description>oral calcitriol 025 mcg BID subjects 11-20 for 20 weeks&#xD;
Calcitriol: Calcitriol is a form of vitamin D given twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Millions of Sperm Per Ejaculate</title>
          <description>Millions of sperm per ejaculate in men treated with 13-cis retinoic acid</description>
          <population>First 10 men received isotretinoin alone, next 10 men received both isotretinoin and calcitriol</population>
          <units>Millions of sperm per ejaculate</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="0.1" upper_limit="5.9"/>
                    <measurement group_id="O2" value="3.8" lower_limit="2.1" upper_limit="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>13-cis Retinoic Acid + Oral Calcitriol</title>
          <description>20 mg 13-cis retinoic acid twice daily (BID) with meals for two weeks + oral calcitriol 0.25 mcg BID</description>
        </group>
        <group group_id="E2">
          <title>13-cis Retinoic Acid</title>
          <description>20 mg 13-cis retinoic acid twice daily (BID) with meals for 20 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. John Amory</name_or_title>
      <organization>University of Washington School of Medicine</organization>
      <phone>2066161727</phone>
      <email>jamory@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

